Sparrow Pharmaceuticals to Present on HSD-1 InhibitorHSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference
08 Jun 2023
Phase 2Phase 1
The company invites visitors to booth #1949 to discuss its mission and clinical programs
PORTLAND, Ore.--(BUSINESS WIRE)-- Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, will present the rationale that its lead candidate and HSD-1 inhibitorHSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.
Presentation title: Intracellular Cortisol Control: An Approach to Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
Presenters: Frank S. Czerwiec, MD, PhD, Chief Medical Officer at Sparrow Pharmaceuticals; David A. Katz, PhD, Chief Scientific Officer, Sparrow Pharmaceuticals; Paul M. Stewart, MD, FRCP, FMedSci, University of Leeds, UK
Presentation number: SAT-281
Session Category: P71 - Clinical Adrenal & Pituitary: Adrenal Basic Science/Animal Models
Date: Saturday, June 17, 2023 at 1:00pm-2:00pm CT
Sparrow is also available to connect with attendees at the company’s booth (#1949) during regular exhibit hours to learn more about Sparrow’s mission and clinical programs.
SPI-62 is a potent HSD-1 inhibitorHSD-1 inhibitor in clinical development for treatment of Cushing’s syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In prior Phase 1 and Phase 2 clinical trials, SPI-62 was associated with maximal liver, adipose, and brain HSD-1 inhibition at generally well tolerated doses.
To learn more about Sparrow Pharmaceuticals SPI-62, visit .
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.